Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Tempus AI, Inc.

< Previous 1 2 Next >
Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces New Study in JCO Precision Oncology Validating PurIST® Algorithm for Enhanced Therapy Selection in Pancreatic Cancer
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Northwestern Medicine Becomes First Health System to Integrate Tempus’ Generative AI Co-Pilot, David, Into Its EHR Platform
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus to Participate in Morgan Stanley’s 23rd Annual Global Healthcare Conference
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces the Acquisition of Paige
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Reports Second Quarter 2025 Results
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus to Report Second Quarter 2025 Financial Results on August 8
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus to Participate in TD Cowen’s 4th Annual Tools/Dx Revolution Conference
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces Collaboration with Northwestern University’s Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer’s Disease Research
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Introducing Tempus One in the EHR with Integrated Guidelines
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 Years
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus to Present at the William Blair 45th Annual Growth Stock Conference
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Reports First Quarter 2025 Results
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus to Report First Quarter 2025 Financial Results on May 6
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.